4D Molecular Therapeutics, Inc. financial data

Symbol
FDMT on Nasdaq
Location
5858 Horton Street #455, Emeryville, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.08K % -51.9%
Debt-to-equity 11.5 % +63.4%
Return On Equity -47.3 % -68.8%
Return On Assets -42.4 % -62%
Operating Margin -508K % -93113%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.8M shares +49.8%
Common Stock, Shares, Outstanding 46.8M shares -10.1%
Entity Public Float 1.04B USD +65.7%
Common Stock, Value, Issued 5K USD 0%
Weighted Average Number of Shares Outstanding, Basic 56.1M shares +1.03%
Weighted Average Number of Shares Outstanding, Diluted 56.1M shares +1.03%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 37K USD -99.8%
Revenue from Contract with Customer, Excluding Assessed Tax 120K USD +567%
General and Administrative Expense 49.3M USD +11.7%
Operating Income (Loss) -230M USD -36.8%
Nonoperating Income (Expense) 21.2M USD -14.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -209M USD -45.8%
Earnings Per Share, Basic -3 USD/shares -35.4%
Earnings Per Share, Diluted -3 USD/shares -35.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 48.6M USD -74.1%
Marketable Securities, Current 257M USD -18.4%
Assets, Current 312M USD -38.8%
Property, Plant and Equipment, Net 16.2M USD -18.7%
Operating Lease, Right-of-Use Asset 18.9M USD -13.1%
Other Assets, Noncurrent 9.38M USD +228%
Assets 424M USD -29.8%
Accounts Payable, Current 6.86M USD +135%
Employee-related Liabilities, Current 9.12M USD -5.06%
Accrued Liabilities, Current 24.2M USD +13%
Contract with Customer, Liability, Current 360K USD +929%
Liabilities, Current 37.1M USD +25.9%
Contract with Customer, Liability, Noncurrent 835K USD -34.8%
Operating Lease, Liability, Noncurrent 16.6M USD -16.1%
Other Liabilities, Noncurrent 144K USD -26.5%
Liabilities 55M USD +7.67%
Accumulated Other Comprehensive Income (Loss), Net of Tax 671K USD -37.8%
Retained Earnings (Accumulated Deficit) -736M USD -39.7%
Stockholders' Equity Attributable to Parent 369M USD -33.3%
Liabilities and Equity 424M USD -29.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -47.8M USD -64.2%
Net Cash Provided by (Used in) Financing Activities 319M USD +2800%
Net Cash Provided by (Used in) Investing Activities 31.9M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 46.8M shares -10.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -15.8M USD -160%
Deferred Tax Assets, Valuation Allowance 128M USD +8.98%
Deferred Tax Assets, Gross 134M USD +9.08%
Operating Lease, Liability 22.3M USD -10.4%
Depreciation 5.1M USD +6.25%
Payments to Acquire Property, Plant, and Equipment 631K USD -11.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -210M USD -46.6%
Lessee, Operating Lease, Liability, to be Paid 29M USD -14.9%
Property, Plant and Equipment, Gross 36.2M USD +2.43%
Operating Lease, Liability, Current 5.7M USD +11.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.35M USD -4.48%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.6M USD -0.66%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.76M USD -27.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.51M USD +2.99%
Deferred Tax Assets, Operating Loss Carryforwards 72.4M USD +21.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 7.08M USD -40.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.68M USD +3%
Operating Lease, Payments 1.4M USD +75%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 24M USD -1.67%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%